article thumbnail

This Common Artificial Sweetener Can Break Down DNA, Scientists Warn

AuroBlog - Aurous Healthcare Clinical Trials blog

The artificial sweetener sucralose (marketed as Splenda) is widely used and found in products like diet soda and chewing gum. According to a new study, it’s also capable of damaging the DNA material inside our cells.

DNA 245
article thumbnail

DNA sequencer Element Bio raises $277m to take on Illumina

pharmaphorum

Element Bio’s bid to take on Illumina in the DNA sequencing market has been helped by an impressive $277m financing round

DNA 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Boundless Bio raises $100m as IPO market rouses

Pharmaceutical Technology

Boundless has two assets in clinical trials targeting extrachromosomal DNA in cancer patients.

DNA 147
article thumbnail

COVID prompts another milestone, as India clears first DNA vaccine

pharmaphorum

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98
article thumbnail

STAT+: Pacific Biosciences, known for niche DNA sequencing, looks to rival Illumina with new product launch

STAT News

firm best known for its niche approach to DNA sequencing, on Tuesday announced plans to launch a new product that will put the company in direct competition with genomics juggernaut Illumina. The new DNA sequencer, dubbed Onso, reads the genome in small pieces and uses software to stitch that information together.

DNA 98
article thumbnail

Sartorius upscales gene therapy prowess with $2.6bn Polyplus acquisition

Pharmaceutical Technology

The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. to complete an in-house plasmid DNA facility in Marburg, Germany. “In In February 2023, the mRNA specialist BioNTech invested $43.8m

article thumbnail

Zydus Cadila nears world-first human plasmid DNA vaccine approval

pharmaphorum

Zydus Cadila has filed for emergency use approval (EUA) in India of its plasmid DNA-based vaccine for COVID-19, which if given a green light could become the first shot of its type to be cleared for widespread use in humans. . The post Zydus Cadila nears world-first human plasmid DNA vaccine approval appeared first on.

DNA 98